CureVac’s Stock Market Journey Concludes Following BioNTech Acquisition
Veröffentlicht: 14.01.2026 um 22:46 Uhr, Redaktion boerse-global.de
The final chapter for Tübingen-based mRNA pioneer CureVac on public markets is now written. A turbulent period in German stock market history, which began with significant promise during the vaccine race, will formally end on January 16, 2026, when its shares are permanently removed from the Nasdaq exchange. This follows the company’s $1.25 billion acquisition by its rival, BioNTech.
For investors, the transition is largely complete. Those who accepted the exchange offer received 0.05363 BioNTech American Depositary Shares (ADS) for each CureVac share they held. At the time the deal was announced, this ratio represented an approximate 55% premium to CureVac’s average trading price.
By the expiration of the offer in December Read more...
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
